Author(s):
Kumaravelrajan R., Janaki. D., Suba V., Guru Prasad Mohanta, Dharani Prasad P.
Email(s):
rkumaravelrajan@gmail.com
DOI:
10.52711/0974-360X.2024.00569 
Address:
Kumaravelrajan R.1*, Janaki. D.1, Suba V.2, Guru Prasad Mohanta3, Dharani Prasad P.4
1Deparatment of Pharmaceutics, C.L. Baid Metha College of Pharmacy, Old Mahabalipuram Rd, Jothi Nagar, Thoraipakkam, Affiliated to The TN Dr.M.G.R. Medical University, Chennai Tamil Nadu, India 600097.
2Department of Pharmacology, National Institute of Siddha under Ministry of Ayush, Affiliated to The TN Dr.M.G.R. Medical University, Chennai – 600047.
3Deparatment of Pharmacy Practice, C.L. Baid Metha College of Pharmacy, Old Mahabalipuram Rd, Jothi Nagar, Thoraipakkam, Affiliated to The TN Dr.M.G.R. Medical University, Chennai Tamil Nadu, India 600097.
4Department of Pharmacology, Mohan Babu University, Tirupati, India.
*Corresponding Author
Published In:
Volume - 17,
Issue - 8,
Year - 2024
ABSTRACT:
The mini-tablets formulations have high patient compliances especially paediatrics and geriatrics The present investigation was to develop and compare HPMC K100 M and HPMC K4 M, a combination of processing variables of 32 factorial design factors, in the formulation of 100mg lamotrigine sustained drug release of mini-tablets for paediatric usage. The amount of lamotrigine in each little tablet is 25mg, and they were made using the direct compression method. Dependent variables included drug release and tensile strength. Drug release was sustained for at least 12 hours across all formulations. The drug release was proportional to the HPMC K4M and HPMC K100M concentrations. The dosages of 2, 4, and 6mg were also kept constant. When mini-tablets prepared with combination of polymers (12mg), F8 exhibits a tensile strength of 3.42N/m2 (6mg). Through numerical optimization, HPMC K4M = 11.0mg and HPMC K100 M = 4.50mg were discovered, resulting in 95.4 percent drug release and 3.1 (N/m2) tensile strength. An in vivo study with the optimized formulation in rats showed (AUC 0-t) and (AUMC 0-t) of 1123.4 (h)* (µg/ml) and 3313 h2* (µg/ml) respectively. Cmax and Tmax were 375.0µg/ml and 4 h.
Cite this article:
Kumaravelrajan R., Janaki. D., Suba V., Guru Prasad Mohanta, Dharani Prasad P.. Novel Paediatric Extended Release Mini-Tablets Formulation and Characterization of Lamotrigine by Design of Experiment (DoE). Research Journal of Pharmacy and Technology. 2024; 17(8):3649-7. doi: 10.52711/0974-360X.2024.00569
Cite(Electronic):
Kumaravelrajan R., Janaki. D., Suba V., Guru Prasad Mohanta, Dharani Prasad P.. Novel Paediatric Extended Release Mini-Tablets Formulation and Characterization of Lamotrigine by Design of Experiment (DoE). Research Journal of Pharmacy and Technology. 2024; 17(8):3649-7. doi: 10.52711/0974-360X.2024.00569 Available on: https://rjptonline.org/AbstractView.aspx?PID=2024-17-8-17
REFERENCES:
1. Ugurlu T. Mini Tablets: A Short Review-Revision. Open J Chem. 2017; 3: 012–22. doi.org/10.17352/ojc.000007
2. Tumulur.V. Drug Delivery Trends. Pharmaceutical mini-tablets. 2020; 12: 123–39.
3. Kokott M, Lura A, Breitkreutz J, Wiedey R. Evaluation of two novel co-processed excipients for direct compression of orodispersible tablets and mini-tablets. Eur J Pharm Biopharm. 2021; 168: 122–30. doi.org/10.1016/j.ejpb.2021.08.016
4. Zhang D, Rumondor ACF, Zhu W, Colace T, Marota M, Mora J, et al. The development of minitablets for a pediatric dosage form for a combination therapy. J Pharm Sci. 2020; 109: 3590–3597. doi.org/10.1016/j.xphs.2020.08.021
5. Aleksovski A, Dreu R, Gašperlin M, Planinšek O. Mini-tablets: a contemporary system for oral drug delivery in targeted patient groups. Expert Opin Drug Deliv. 2015; 12: 65–84. doi.org/10.1517/17425247.2014.951633
6. Eberle VA, Häring A, Schoelkopf J, Gane PA, Huwyler J, Puchkov M. In silico and in vitro methods to optimize the performance of experimental gastroretentive floating mini-tablets. Drug Dev Ind Pharm. 2016; 42: 808-817. doi.org/10.3109/03639045.2015.1078350
7. Sabarathinam J, Maheswari TNU. Assessment of behavioural management techniques of paediatric patients among the dentist in Chennai: A questionnaire study. Research Journal of Pharmacy and Technology. 2016; 9: 145. http://dx.doi.org/10.5958/0974-360x.2016.00024.x
8. Mitra B, Chang J, Wu S-J, Wolfe CN, Ternik RL, Gunter TZ, et al. Feasibility of mini-tablets as a flexible drug delivery tool. Int J Pharm. 2017; 525: 149–59. doi.org/10.1016/j.ijpharm.2017.04.037
9. Roberts M, Vellucci D, Mostafa S, Miolane C, Marchaud D. Development and evaluation of sustained-release Compritol® 888 ATO matrix mini-tablets. Drug Dev Ind Pharm. 2012; 38: 1068–1076. doi.org/10.3109/03639045.2011.638302
10. Jagadeesan M, Harini RR, Chinnasami B. Rational Prescribing Challenges in Paediatrics: A Evidence Based Review. Research Journal of Pharmacy and Technology. 2020; 13: 5551–6.
11. Bhuvaneshwari S, Umashankar M S, Damodharan N. Mini Tablets: Pediatric Drug Delivery System. Research Journal of Pharmacy and Technology. 2020; 13: 2985-2991.
12. Besag FM, Wallace SJ, Dulac O, Alving J, Spencer SC, Hosking G. Lamotrigine for the treatment of epilepsy in childhood. J Pediatr. 1995; 127: 991-997. doi.org/10.1016/s0022-510x(97)86362-9
13. Jain R, S. Iyer S, Radhakrishnan P, Kumar S, H. Khuroo A, Monif T. Development and validation of “; Level A”; In vitro - in vivo correlation for extended release tablets of lamotrigine. Curr Bioact Compd. 2016; 12: 289–296.
14. Kumar Satpathy T, Chaubey N, Kumar Brahma C, Maheshwari M. 2022. Formulation and evaluation of lamotrigine loaded nanosponges. Research Journal of Pharmacy and Technology. 2022; 15: 229-235. doi.org/10.52711/0974-360x.2022.00038
15. Reddy DV, Rao AS. A review on oral extended release technology. Research Journal of Pharmacy and Technology. 2015; 8: 1454. http://dx.doi.org/10.5958/0974-360x.2015.00261.9
16. Nigam K, Kaur A, Tyagi A, Manda K, Goswami N, Nematullah M, et al. In vitro and in vivo evaluations of PLGA nanoparticle based combinatorial drug therapy for baclofen and lamotrigine for neuropathic pain management. J Microencapsul. 2022; 01–15. doi.org/10.1080/02652048.2022.2041751
17. Shaikh S, Patel H, Ray D, Aswal VK, Sharma RK. Mixed Poloxamer nanomicelles for the anticonvulsant lamotrigine drug: Solubility, micellar characterization, and in-Vitro release studies. J Nanosci Nanotechnol. 2021; 21: 5723–5735. doi.org/10.1166/jnn.2021.19490
18. Ma C, Huang Z, Zhu Y, Chen X, Singh V, Huang Y, et al. Production and in vitro evaluation of a lamotrigine extended release tablet based on a controlled-porosity osmotic pump system. Pharmazie. 2017; 72: 511–517. doi.org/10.1691/ph.2017.7054
19. Jafri I, Shoaib MH, Yousuf RI, Ali FR. Effect of permeation enhancers on in vitro release and transdermal delivery of lamotrigine from Eudragit®RS100 polymer matrix-type drug in adhesive patches. Prog Biomater. 2019; 8: 091–100. doi.org/10.1007/s40204-019-0114-9
20. Mohana Raghava Srivalli K, Lakshmi PK, Balasubramaniam J. Design of a novel bilayered gastric mucoadhesive system for localized and unidirectional release of lamotrigine. Saudi Pharm J. 2013; 21: 45–52. doi.org/10.1016/j.jsps.2012.01.004
21. Mishra B, Sahoo BL, Mishra M, Shukla D, Kumar V. Design of a controlled release liquid formulation of lamotrigine. Daru. 2011; 19: 126–137.
22. Shah HJ, Subbaiah G, Patel DM, Patel CN. In vitro-in vivo correlation of modified release dosage form of lamotrigine: In Vitro-In Vivo Correlation of Modified Release Lamotrigine. Biopharm Drug Dispos. 2009; 30: 524–31. doi.org/10.53879/id.58.12.12701
23. Prannoy T, Lakshmi PK. Design and optimization of hydrodynamically balanced oral in-situ gel of lamotrigine. Research Journal of Pharmacy and Technology. 2020; 13: 4865. http://dx.doi.org/10.5958/0974-360x.2020.00856.2
24. Rajesh B, Nawale UA, Sadhana R, Shahi PM. Formulation and Characterization of Efavirenz Nanosuspension by QbD approach. Research Journal of Pharmacy and Technology. 2017; 10: 2960–72
25. Kumaravelrajan R., Thirumaran M., Sangavi T and Suba V. Preparation and Evaluation of Active Film Coating Tablet of Teneligliptin Hydrobromide Hydrate with Metformin Hydrochloride Fixed Dose Combination. Indian Drugs. 2021; 58: 22-31.
26. Statistical Optimization of Orodispersible Tablets Containing Telmisartan Using Factorial Design and Response Surface Methodology. Research Journal of Pharmacy and Technology. 2009; 2: 548–51.
27. Kotadiya RM, Patel VA, Patel HV. Factorial Design Based Formulation and Characterization of the Controlled Release Methotrexate Beads. Research Journal of Pharmacy and Technology. 2009; 2: 592–6.
28. Błaszczyk B, Czuczwar SJ. Efficacy, safety, and potential of extended-release lamotrigine in the treatment of epileptic patients. Neuropsychiatr Dis Treat. 2010; 6: 145-150. doi.org/10.2147/ndt. s6515
29. Palugan L, Filippin I, Cirilli M, Moutaharrik S, Zema L, Cerea M, et al. Cellulase as an “active” excipient in prolonged-release HPMC matrices: A novel strategy towards zero-order release kinetics. Int J Pharm. 2021; 607: 01-08. doi.org/10.1016/j.ijpharm.2021.121005
30. Porat D, Azran C, Mualem Y, Vainer E, Gibori R, Vaynshtein J, Dukhno O, Dahan A. Lamotrigine therapy in patients after bariatric surgery: Potentially hampered solubility and dissolution. Int J Pharm. 2022; 612: 121298. doi.org/10.1016/j.ijpharm.2021.121298
31. Bhardwaj P, Shailendra K, Sharma DS, Sharma A, Kulkarni MP, Singh SK, Singh VP, Singh G, Kumar P, Kumar R. Chewable Tablets of Acacia Catechu Extract, an Alternative to Betel (Paan) for Mouth Ulcers: Formulation and In vitro Evaluation. Curr Drug Deliv. 2021; 18: 500-512. doi.org/10.2174/1567201817999200728140352
32. Barros PD, Dias IFT, Zanin GD, Bunhak ÉJ. Development and evaluation of dapsone tablets coated for specific colon release. Drug Dev Ind Pharm. 2020; 46: 246-252. doi.org/10.1080/03639045.2020.1716375
33. Culy CR, Goa KL. Lamotrigine. A review of its use in childhood epilepsy. Paediatr Drugs. 2000; 2: 299-330.
34. Fitton A, Goa KL. Lamotrigine. An update of its pharmacology and therapeutic use in epilepsy. Drugs. 1995; 50: 691-713.
35. Indian Pharmacopoeia Commission. Indian Pharmacopoeia 2014 (4 Vol Set). 7th ed. Indian Pharmacopoeia Commission; 2013.
36. Lalic M, Pilipovic A, Golocorbin-Kon S, Gebauer-Bukurov K, Bozic K, Mikov M, Cvejic J. Comparison of dissolution profiles and serum concentrations of two lamotrigine tablet formulations. Drugs R D. 2011; 11: 53-60. doi.org/10.1007/bf03259794
37. Swati V, Patel A, Patel S, Neelesh D. Formulation and Evaluation of Controlled Release Tablet of Lamotrigine. International Journal of Pharmaceutical and Biological Archives, 2018; 9:151-156.
38. Jarosz, P. J., & Parrott, E. L. Tensile strengths and hardness of tablets. Journal of Pharmaceutical Sciences, 1982: 71: 705–707. doi.org/10.1002/jps.2600710625
39. Odeku, O. A., and Itiola, O. A. Effects of interacting variables on the tensile strength and the release properties of paracetamol tablets. 2009: 51: 141-148.
40. Kumaravelrajan R, Mohan Raj V, Thirumaran M, Suba V. Application of Factorial Design in the Premixing Operation of Diltiazem Timed-Release Pellets. Indian J Pharm Sci. 2022; 84 :390-399. doi.org/10.36468/pharmaceutical-sciences.932
41. Mohan A, Gundamaraju R. In vitro and in vivo evaluation of fast-dissolving tablets containing solid dispersion of lamotrigine. Int J Pharm Investig. 2015; 5: 57–64. doi.org/10.4103/2230-973X.147235.
42. Prusty A, K Gupta B, Mishra A. Formulation and in vivo evaluation of pharmacokinetics parameters of extended release matrix tablet containing drug Benidipine Hydrochloride by using PK solver software. Research Journal of Pharmacy and Technology. 2022; 4924–30. http://dx.doi.org/10.52711/0974-360x.2022.00827
43. PK Solutions. Summit Research Services, Montrose, CO 81401; 2003. www.SummitPK.com.
44. Koteswari P, Sunium S, Srinivasababu P, Babu GK, Nithya PD. Formulation Development and evaluation of fast disintegrating tablets of Lamotrigine using liqui-solid technique. Int J Pharm Investig. 2014; 4 :207-214.
45. Kamble D, Singhavi D, Tapadia S, Khan S. Investigation of Pectin-Hydroxypropyl Methylcellulose-Coated Floating Beads for Pulsatile Release of Piroxicam. Turk J Pharm Sci. 2020; 17: 542-548. doi.org/10.4274/tjps.galenos.2019.99896
46. Poonuru RR, Gonugunta CSR. Bimodal gastro retentive drug delivery systems of lamotrigine: formulation and evaluation. Indian J Pharm Sci. 2014; 76: 476–482.
47. Mohamed FAA, Roberts M, Seton L, Ford JL, Levina M, Rajabi-Siahboomi AR. The effect of HPMC particle size on the drug release rate and the percolation threshold in extended-release mini-tablets. Drug Dev Ind Pharm. 2015; 41:70–8. doi.org/10.3109/03639045.2013.845843
48. Pitt KG, Heasley MG. Determination of the tensile strength of elongated tablets. Powder Technol [Internet]. 2013; 238: 169–75. doi.org/10.1016/j.powtec.2011.12.060
49. Fukuda IM, Pinto CFF, Moreira C dos S, Saviano AM, Lourenço FR. Design of experiments (DoE) applied to pharmaceutical and analytical quality by design (QbD). Braz J Pharm Sci. 2018; 54(spe) doi.org/10.1590/s2175-97902018000001006
50. Dejaegher B, Heyden YV. Experimental designs and their recent advances in set-up, data interpretation, and analytical applications. J Pharm Biomed Anal [Internet]. 2011; 56(2): 141–58. doi.org/10.1016/j.jpba.2011.04.023
51. Hejduk, A., Teżyk, M., Jakubowska, E. et al. Implementing the Design of Experiments (DoE) Concept into the Development Phase of Orodispersible Minitablets (ODMTs) Containing Melatonin. AAPS Pharm Sci Tech. 23, 60 (2022). doi.org/10.1208/s12249-021-02185-6
52. Shah P, Dubey P, Vyas B, Kaul A, Mishra AK, Chopra D, et al. Lamotrigine loaded PLGA nanoparticles intended for direct nose to brain delivery in epilepsy: pharmacokinetic, pharmacodynamic and scintigraphy study. Artif Cells Nanomed Biotechnol. 2021; 49: 511–522. doi.org/10.1080/21691401.2021.1939709
53. Bakhaidar, Rana B., Nimbagal Raghavendra Naveen, Pratap Basim, Samar S. Murshid, Mallesh Kurakula, Abdulmohsin J. Alamoudi, Deena M. Bukhary, Abdulmajeed M. Jali, Mohammed A. Majrashi, Sameer Alshehri, and et al. Response Surface Methodology (RSM) Powered Formulation Development, Optimization and Evaluation of Thiolated Based Mucoadhesive Nanocrystals for Local Delivery of Simvastatin. Polymers. 2022; 14(23): 5184. doi.org/10.3390/polym14235184
54. Siepmann J, Peppas NA. Modeling of drug release from delivery systems based on hydroxypropyl methylcellulose (HPMC). Adv Drug Deliv Rev. 2012; 163–174. doi.org/10.1016/j.addr.2012.09.028
55. Costa P, Sousa Lobo JM. Modeling and comparison of dissolution profiles. Eur J Pharm Sci. 2001; 13: 123–133. doi.org/10.1016/s0928-0987(01)00095-1
56. Ammar HO, Ghorab MM, Mahmoud AA, Higazy IM. Lamotrigine loaded poly-ɛ-(d,l-lactide-co-caprolactone) nanoparticles as brain delivery system. Eur J Pharm Sci. 2018; 30; 2: 77-87. doi.org/10.1016/j.ejps.2018.01.028